AMDL Signs Second Significant New Distribution Relationship for Shanghai Market
May 14 2007 - 7:00AM
PR Newswire (US)
TUSTIN, Calif., May 14 /PRNewswire-FirstCall/ -- AMDL, Inc.
(AMEX:ADL), headquartered in Tustin, California, with operations in
Shenzhen, Jiangxi and Jilin China, through its wholly owned
subsidiary Jade Pharmaceutical Inc. (JPI), is an international
biopharma company. AMDL together with Jade engages in the
development, manufacture and marketing of proprietary
pharmaceutical and testing products. AMDL announced today that
Jade, through its subsidiary JJB, has signed a new Distribution and
Agency Agreement with Shanghai SiFul Medicine Co., Ltd., (Shanghai
SiFul), an indirect subsidiary of China Resources (Holdings) Co.,
Ltd. (China Resources). This one-year renewable agreement covers
primarily the city of Shanghai. Shanghai SiFul will initially be
selling 12 various Jade products including Ondansetron Injectables,
Domperidon Tablets, Chondroitin Sulfate Injectables, GuYanLin
Compounds, Benzoic Acid /Camphor Solutions, Levofloxacin and
Lactate Injectables and others. Mr. Frank Zheng, Managing Director
of JPI, stated that "the total population of Shanghai is over 20
million people, with one of the most affluence population bases
within China today. Gaining market share for JPI's products in this
key China market is a cornerstone of our sales growth strategy.
This new distribution agreement with Shanghai SiFul, coupled with
the new distribution relationship recently announced with Double
Crane Medicine Co. Ltd. (Changsha), both require JJB's distribution
partners to meet minimum sales thresholds of approximately (US)
$3.8 million annually or a total of (US) $7.6 million for these two
contracts. Based upon both distribution agreements and discussions
between JJB and its new distribution partners, there is a potential
to increase JPI's sales in Southern China and the Shanghai regional
markets by as much as (US) $16 million over the next 12 month sales
cycle. Ondansetron injectables are expected to be the biggest
selling product in the Shanghai hospital marketplace." Mr. Gary
Dreher, CEO of AMDL noted that that this "new regional Chinese
distribution relationship with Shanghai SiFul is truly exciting and
significantly enhances JPI's ability to grow its sales in this key
China market." About Jade: Jade has access to the fastest growing
pharmaceutical and consumer market in the world: China. AMDL,
through its subsidiaries, Jade currently manufactures large volume
injection fluids, tablets and other related products, holding
licenses for 133 products. It also manufactures generic, over the
counter and supplemental pharmaceutical products under certified
Chinese Good Manufacturing Practice (CGMP) standards. About
Shanghai SiFul: Shanghai SiFul is an indirect subsidiary of China
Resources. Shanghai SiFul's 2006 sales were approximately (US) $80
million. Shanghai SiFul's sales activities are nearly all focused
on the Shanghai market. China Resources began its history in Hong
Kong in 1938 as Liow & Company. It was renamed China Resources
Company in 1948 and restructured and incorporated under China
Resources (Holdings) Co., Ltd. in 1983. In the same year, it
relocated to its current headquarters in the China Resources
Building on 26 Harbour Road, Wanchai. With more than a half
century's business in Hong Kong, China Resources has established a
strong reputation based on its proactive business strategies, an
open corporate culture and a commitment to fostering a better
future. Today, it is one of the leading conglomerates in Hong Kong
and the Chinese Mainland, with assets totaling approximately (US)
$14 Billion. About AMDL: AMDL, Inc., headquartered in Tustin,
California, with operations in Shenzhen, Jaingxi and Jilin China
through its wholly owned subsidiary Jade Pharmaceutical Inc., is an
international biopharma company. AMDL together with Jade engages in
the development, manufacture and marketing of proprietary
pharmaceutical and testing products. More information about AMDL
and its products can be obtained at http://www.amdl.com/.
Forward-Looking Statements: This news release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are
subject to certain risks and uncertainties, and actual
circumstances, events or results may differ materially from those
projected in such forward-looking statements. The Company cautions
readers not to place undue reliance on any forward-looking
statements. The Company does not undertake, and specifically
disclaims any obligation, to update or revise such statements to
reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc. Gary L. Dreher President & CEO (714)
505-4460 DATASOURCE: AMDL, Inc. CONTACT: AMDL, Inc., Gary L.
Dreher, President & CEO, +1-714-505-4460 Web site:
http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From May 2024 to Jun 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2023 to Jun 2024